Alan M. Kirschenbaum
For more than 20 years, Alan M. Kirschenbaum has advised pharmaceutical and medical device companies on the marketing and promotion of their products. He specializes in the intersection of laws that govern these activities, including health care fraud and abuse laws, FDA restrictions on promotion, government pricing and price reporting requirements, and state drug and device marketing laws.
In the area of promotion and marketing, Mr. Kirschenbaum helps clients design marketing programs within the bounds of the health care fraud and abuse laws, FDA restrictions on promotion, and state marketing prohibitions. He helps clients build their in-house compliance capabilities by developing policies and procedures, providing training, and conducting internal audits. He assists with drafting and reviewing agreements among partners throughout the distribution and payment chains, including manufacturers, distributors, providers, pharmacy benefit managers, health plans, and other entities. He also advises clients on transparency reporting at the state and federal level.
Mr. Kirschenbaum's work in government pricing includes advising companies on requirements for price reporting to the federal and state governments, meeting requirements for government discount and rebate programs, and contracting with the federal government. As part of this work, Mr. Kirschenbaum negotiates with the Centers for Medicare & Medicaid Services, the Department of Veterans Affairs, and other federal and state government agencies on behalf of clients.
Mr. Kirschenbaum frequently writes articles and gives lectures on developments in drug and device promotion and marketing law. Before entering private practice in 1990, Mr. Kirschenbaum served as a law clerk for Judge Theodore R. Newman of the District of Columbia Court of Appeals.
Promotion and Marketing
• Helps companies design compliant marketing programs and sales practices.
• Develops sales and marketing compliance policies and procedures.
• Conducts internal compliance audits and investigations.
• Drafts and reviews agreements among manufacturers, distributors, providers, PBMs, GPOs, and other entities in the distribution and payment chains.
• Conducts training for sales, legal, and management personnel.
• Advises clients on federal and state transparency reporting requirements.
Government Pricing and Contracting
• Helps companies comply with government price reporting and discounting requirements, including the Medicaid Drug Rebate Program, reporting of ASP and NFAMP, 340B Program pricing limitations, and price reporting to Texas and other states.
• Provides counsel on FSS and other federal contracting issues.
• Helps clients develop policies, procedures, and training for government pricing compliance.
D.C. Bar Health Law Section, former member of its Steering Committee
American Health Lawyers Association
Awards & Recognition
• Who's Who Legal Directory, Life Sciences, Regulatory Section, 2015-2016
Articles / Publications
see more articles
• HPM/KPMG Webinar: A Practical Guide to the MDRP Final Rule,
February 19, 2016
• Summary of MDRP Final Rule,
February 01, 2016
• Summary of HRSA 340B Proposed Guidance,
September 3, 2015
• Application of Health Care Fraud and Abuse Laws to the Marketing of Pharmaceuticals and Medical Devices,
January 5, 2014
• Summary of CMS Final Rule on Transparency Reporting,
February 12, 2013
see more speaking engagements
• American Pharmacists' Association (APhA) Annual Meeting, 3/5 Speech: Radiopharmaceutical Compounding - Past and Present, March 4-7, 2016
• Medicaid Rebate Final Rule Published in Federal Register; HP&M Issues Summary, Schedules Webinar, February19, 2016
• Webinar - A Practical Guide to the Medicaid Drug Rebate Program Final Rule, February 19, 2016
• Annual Medicaid and Government Pricing Congress, AMK 6/4 Workshop Leader: “Access and Address Your Organization’s Needs”, June 3-5, 2015
• ACI - Prescription Drug Pricing, Final AMP Rule Forecast, June 23-24, 2014
see more blog entries
• Nevada Scares Diabetes Drug Manufacturers With Halloween List of “Essential Diabetes Drugs”,
November 9, 2017
• 2017: A Banner Year for State Laws on Drug Pricing, Price Reporting, and Discounting,
November 2, 2017
• PhRMA and BIO Team Up Again to Challenge a State Drug Pricing Law,
September 7, 2017
• HHS Proposes Longer Delays to Implementation of the 340B Final Rule,
August 21, 2017
• Nevada Transparency Bill Targets Diabetes Drugs and Payments to Health Care Providers,
June 20, 2017